PEA‐15 (Phosphoprotein Enriched in Astrocytes 15) Is a Protective Mediator in the Vasculature and Is Regulated During Neointimal Hyperplasia by Greig, Fiona H et al.
PEA-15 (Phosphoprotein Enriched in Astrocytes 15) Is a Protective
Mediator in the Vasculature and Is Regulated During Neointimal
Hyperplasia
Fiona H. Greig, PhD; Simon Kennedy, PhD; George Gibson, MBChB; Joe W. Ramos, PhD; Graeme F. Nixon, PhD
Background-—Neointimal hyperplasia following angioplasty occurs via vascular smooth muscle cell proliferation. The mechanisms
involved are not fully understood but include mitogen-activated protein kinases ERK1/2 (extracellular signal–regulated kinases 1
and 2). We recently identiﬁed the intracellular mediator PEA-15 (phosphoprotein enriched in astrocytes 15) in vascular smooth
muscle cells as a regulator of ERK1/2-dependent proliferation in vitro. PEA-15 acts as a cytoplasmic anchor for ERK1/2,
preventing nuclear localization and thereby reducing ERK1/2-dependent gene expression. The aim of the current study was to
examine the role of PEA-15 in neointimal hyperplasia in vivo.
Method and Results-—Mice deﬁcient in PEA-15 or wild-type mice were subjected to wire injury of the carotid artery. In uninjured
arteries from PEA-15–deﬁcient mice, ERK1/2 had increased nuclear translocation and increased basal ERK1/2-dependent
transcription. Following wire injury, arteries from PEA-15–deﬁcient mice developed neointimal hyperplasia at an increased rate
compared with wild-type mice. This occurred in parallel with an increase in a proliferative marker and vascular smooth muscle cell
proliferation. In wild-type mice, PEA-15 expression was decreased in vascular smooth muscle cells at an early stage before any
increase in intima:media ratio. This regulation of PEA-15 expression following injury was also observed in an ex vivo human model
of hyperplasia.
Conclusions-—These results indicate, for the ﬁrst time, a novel protective role for PEA-15 against inappropriate vascular
proliferation. PEA-15 expression may also be repressed during vascular injury, suggesting that maintenance of PEA-15 expression
is a novel therapeutic target in vascular disease. ( J Am Heart Assoc. 2017;6:e006936. DOI: 10.1161/JAHA.117.006936.)
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A rterial occlusion caused by atherosclerotic plaqueformation is typically treated using balloon angioplasty
and arterial stent placement. Approximately 25% to 30% of
patients subsequently require reintervention to treat rest-
enotic arteries.1 Restenosis is predominantly the result of
excessive vascular smooth muscle cell (VSMC) proliferation,
initiated in part by an inﬂammatory component, that leads to
neointimal hyperplasia.2,3 Drug-eluting stents have attempted
to prevent neointimal hyperplasia by decreasing VSMC
proliferation via inhibition of the cell growth cycle but can
have undesirable side effects, including late stent failure, that
have limited any widespread clinical use.1–3 Other approaches
or targets are required to address this unmet clinical need.
In neointimal hyperplasia, an increase in growth factors,
including PDGF BB (platelet-derived growth factor BB), results
in an increase in proliferative genes and a decrease in smooth
muscle marker genes.3,4 This change in cell phenotype occurs
via ligand engagement of growth factor receptor tyrosine
kinases, leading to activation of signaling cascades including
the canonical ERK1/2 (extracellular signal-regulated kinase
1/2) pathway.4,5 ERK1/2 is a key regulatory element in the
control of transcription following initiation of VSMC prolifer-
ation.4–6 Following its activation, ERK1/2 translocates to the
nucleus to directly phosphorylate the Ets transcription factor
Elk-1 (ETS-like gene-1), ultimately inducing expression of
genes that play primary roles in proliferation.6–8 Such
evidence indicates that growth factor–induced activation of
ERK1/2 is critical during the initiation of a proliferative
phenotype in differentiated VSMCs. We recently identiﬁed an
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ERK1/2 binding protein, PEA-15 (phosphoprotein enriched in
astrocytes 15, also known as proliferation and apoptosis
adapter protein 15), that was previously uncharacterized in
the cardiovascular system and that has an important regu-
latory role in maintaining VSMC phenotype.9
Although PEA-15 has been examined in relatively few cell
types to date, studies have revealed that PEA-15 binds to and
sequesters ERK1/2 in the cytoplasm, that is, it acts as a
cytoplasmic anchor.9–12 The predominant localization of PEA-
15 in the cell cytoplasm is due to the presence of a nuclear
export sequence.10 Although PEA-15 is one of many ERK1/2
binding proteins, it is unique in its anchoring role.11,12 PEA-15
does not alter ERK1/2 activation (as we have shown in
VSMCs) but rather its downstream effects, which include
nuclear translocation and protein scaffolding.9,11,12 PEA-15
has 2 phosphorylation sites that may be important in altering
ERK1/2 binding.9,13 In VSMCs, our previous study demon-
strated that phosphorylation of these sites by growth factor–
induced phospholipase Cc activation releases ERK1/2 from
PEA-15 binding, allowing ERK1/2 to translocate to the
nucleus.9 Consequently, this interaction mediates ERK1/
2-induced gene expression.9,13,14
In differentiated VSMCs in the absence of growth factors,
PEA-15 prevents ERK1/2 translocation to the nucleus and
limits ERK1/2-mediated gene transcription.9 This maintains
VSMCs in a quiescent phenotype and could be an important
protective mechanism in vivo against the development of
vascular disease. In addition, decreased expression of PEA-15
in VSMCs in culture using small interfering RNA knockdown,
results in an increase in proliferation.9 In the present study, we
hypothesized that PEA-15 could have important implications for
the development of neointimal hyperplasia following angio-
plasty. To examine this hypothesis, we used a wire injury model
in arteries frommice deﬁcient in PEA-15 (PEA-15/). The data
obtained indicate that PEA-15 expression is critical for regulat-
ing neointimal hyperplasia and may provide a novel therapeutic
target to decrease restenosis following angioplasty.
Materials and Methods
Transgenic Mice
PEA-15/ mice were generated by homologous recombina-
tion, as described previously.15 Animals were maintained on a
normal chow diet in speciﬁc pathogen-free conditions. All
animal experiments were approved by the University of
Aberdeen Ethics Board and performed following UK Home
Ofﬁce license PPL70/8572 under the Animals (Scientiﬁc
Procedures) Act 1986. Male PEA-15/ mice were used at
8 weeks of age (n=12 per group), and all experiments were
compared with back-crossed C57BL/6 wild-type (WT) age-
matched animals (also n=12 per group).
Cell Culture
Following euthanasia by CO2 inhalation and cervical disloca-
tion, aortae were dissected from mice, and primary aortic
smooth muscle cultures were established using enzymatic
digestion, as described previously.16
Cryosectioning and Confocal Immunomicroscopy
Blood vessels were dissected and incubated (if required) as
indicated at 37°C. Tissues were ﬁxed, ﬂash frozen, sectioned,
and immunolabeled, as described previously.16 All control
sections had negligible background staining only. For analysis
of immunoﬂuorescent images, 4 ﬁelds of view were taken
from each sample, and the ﬂuorescence intensity was
measured using ImageJ (National Institutes of Health). For
routine staining, carotid arteries were ﬁxed overnight in
formalin, embedded in parafﬁn, and cut to 4 lm on a
microtome. Slides were stained with hematoxylin and eosin.
Immunoblots
Arteries were dissected free from connective tissue. Tissue
was ﬂash frozen in liquid N2 and crushed using a glass
homogenizer. Protein extracts were prepared and subjected
to SDS-PAGE followed by immunoblotting, as described
previously.16
Electromobility Shift Assay
Denuded aortae were stimulated with PDGF (50 ng/mL) for
30 minutes. Nuclear fractions were prepared, as described
Clinical Perspective
What Is New?
• The intracellular mediator PEA-15 (phosphoprotein enriched
in astrocytes 15) is an important regulatory protein in
arteries and acts as a protective mechanism against the
development of restenosis.
• PEA-15 expression is decreased during neointimal develop-
ment, leading to increased proliferation of vascular smooth
muscle cells.
What Are the Clinical Implications?
• Maintaining PEA-15 expression (by mechanisms yet to be
determined) following arterial stent placement could
decrease the development of neointimal hyperplasia by
preventing excessive vascular smooth muscle cell
proliferation.
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previously.17 Protein (1 lg) from nuclear preparations was
used in each experiment. Protocols were carried out accord-
ing to the manufacturer’s instructions (Active Motif). For
competition experiments, cold probe was added in addition to
the biotin-labeled probe. Protein–DNA complexes were
resolved on a 6% polyacrylamide gel. Bands were visualized
using a streptavidin–horseradish peroxidase detection
reagent.
Carotid Artery Wire Injury
Immediately before surgery, 8-week-old male mice received
an intraperitoneal injection of an analgesic, buprenorphine
(0.1 mg/kg), and 2.5 mg of the antiplatelet drug dipyri-
damole. Sterile saline (0.5 mL via subcutaneous injection)
was also administered to prevent dehydration of the animal
during surgery. All surgical procedures were performed under
aseptic conditions. Carotid artery injury surgery was per-
formed following an adapted method described by our labo-
ratory.18 General anesthesia was induced by 3% (vol/vol)
isoﬂurane supplemented with oxygen (ﬂow rate of 0.5 L/min)
and maintained at 1.5% (vol/vol) isoﬂurane via a face mask
throughout the procedure. The depth of anesthesia was
monitored throughout the surgery using the hind limb reﬂex
with the other paws secured with tape. A small skin incision
was made in the ventral side of the neck to expose the
trachea. Blunt dissection was performed to navigate through
muscle and connective tissue inferior to the trachea, exposing
about 0.5 cm of the left common carotid artery. Precise
dissection was used to detach the vagus nerve from the
artery, and 2 silk ligatures (size 6-0) were positioned at the
proximal and distal ends of the vessel. The distal ligature was
tied tightly, and an arterial clip was positioned at the most
proximal end to temporarily occlude the blood ﬂow in the
vessel. A small incision was made in the artery, and a piece of
a modiﬁed ﬂexible nylon wire, adapted by melting the end to
create a blunt spherical tip, was inserted into the incision site
and held loosely in place by tightening of the proximal
ligature. Once the arterial clip was removed, the nylon wire
was advanced and rotated down the carotid artery into the
thoracic aorta, and this was repeated several times to ensure
the removal of the endothelium. Once the nylon wire was
removed, the arterial clip was replaced, and the proximal
ligature was tied tightly and secured just below the incision
site. On removal of the clip, the area was bathed with
heparinized saline, and a continuous line of subcutaneous
sutures (size 6-0 [Vircyl; Ethicon]) was used to close the skin
incision. For postoperative care, the mice received an
intraperitoneal injection of buprenorphine (0.1 mg/kg) and
were transferred to a heating mat and maintained at 37°C
until recovery. Sham-operated mice were studied as controls
following the same procedure without the insertion of the
nylon wire. The contralateral uninjured arteries were also
assessed. Mice were euthanized at 7, 14, or 28 days after the
carotid artery injury surgery by intraperitoneal injection of
200 mg/kg of sodium pentobarbital to allow for tissue
collection.
Neointimal hyperplasia was determined by measuring the
intimal and medial layers in arterial sections using ImageJ
software.
Human Saphenous Vein Organ Culture
Saphenous veins were obtained from patients undergoing
coronary artery bypass grafting surgery after obtaining written
consent under procedures approved by the local ethics
committee (National Research Ethic Committee–North of
Scotland, reference 06/S0802/26). Veins from 6 different
patients were used. These procedures conform to the
principles outlined in the Declaration of Helsinki. For ex vivo
organ culture, veins were incubated in 30% bovine calf serum
and Dulbecco’s modiﬁed Eagle’s medium for 14 days at 37°C
in 95% O2/5% CO2 with medium changed every 48 hours.
Quantitative Polymerase Chain Reaction
Following treatments, RNA was extracted from human
saphenous vein segments cells using TRIzol (Invitrogen),
according to the manufacturer’s instructions. Quantitative
real-time polymerase chain reaction was performed using
TaqMan gene expression assays from Applied Biosystems, as
described previously.9 Samples were analyzed using a Light-
cycler 480 system for real-time polymerase chain reaction
(Roche Applied Biosystems). Changes in gene expression for
PEA-15, smooth muscle myosin heavy chain, and Ki67 were
expressed as a ratio of the corresponding GAPDH. The same
results were obtained when expressed as a ratio of b-actin
(not shown).
Materials
Antibodies against ERK1/2, phosphorylated ERK1/2, smooth
muscle a-actin, PEA-15, proliferating cell nuclear antigen,
CD68, Ki67, and GAPDH were from Santa Cruz Biotechnology.
All tissue culture reagents were purchased from Life Tech-
nologies. All other reagents were purchased from Sigma-
Aldrich.
Statistical Analyses
Data are expressed as the meanSEM. Statistical analysis
was performed using Prism software (GraphPad Software). For
single comparisons, an unpaired t test was applied. For
multiple comparisons, as appropriate, either 1-way ANOVA
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followed by a Newman–Keuls post hoc test or 2-way ANOVA
with a Bonferroni post hoc test was used. P<0.05 was
considered statistically signiﬁcant.
Results
Phenotype of VSMCs in PEA-15/ Mice
The mean arterial pressure, systolic blood pressure, diastolic
blood pressure, and heart rate in 8-week-old male PEA-15/
mice were not signiﬁcantly different from age-matched WT
C57/BL6 male mice. In addition, there was no signiﬁcant
difference in mean heart wet weight (data not shown).
We previously showed in cultured human coronary artery
VSMCs that a small interfering RNA–induced knockdown of
PEA-15 expression results in increased localization of ERK1/2
to the nucleus and, consequently, an increase in VSMC
proliferation.9 In this study, ERK1/2 localization in unstimu-
lated VSMCs cultured from the aortae of PEA-15/ mice was
predominantly nuclear (Figure 1A) compared with the cyto-
plasmic localization in cultured VSMCs from WT mice,
in agreement with our previous study. We further exam-
ined ERK1/2 localization in freshly isolated arteries from
PEA-15/ mice. Similarly, ERK1/2 was localized predomi-
nantly to the nucleus in carotid arteries from PEA-15/ mice,
and this was signiﬁcantly different from WT arteries with
mostly cytoplasmic ERK1/2 distribution (Figure 1B). To
determine whether this altered ERK1/2 localization affected
ERK1/2 activation, aortae from PEA-15/ mice were
incubated with 50 ng/mL PDGF for 15 minutes, and tissue
homogenates were subjected to immunoblotting with anti–
phospho-ERK1/2 antibody (Figure 1C). Interestingly, com-
pared with WT aortae, which produced a signiﬁcant increase
in ERK1/2 phosphorylation following PDGF stimulation,
aortae from PEA-15/ mice did not demonstrate any change
in ERK1/2 phosphorylation (although a level of basal ERK1/2
phosphorylation was still maintained). This could be due to
ERK1/2 being shielded from upstream activators as a result
of its increased nuclear localization. Directly downstream of
ERK1/2, the nuclear-resident transcription factor Elk-1 is
directly activated by ERK1/2 in the nucleus and is important
in VSMC proliferation.6–8 In this study, we sought to determine
whether Elk-1 activation was altered when ERK1/2 was not
tethered to PEA-15 in the cytoplasm. Aortae from PEA-15/
or WT mice were stimulated with 50 ng/mL PDGF for
15 minutes, and the activation of Elk-1 transcription was
measured using an electromobility shift assay (Figure 1D). In
WT aortae, PDGF incubation produced a signiﬁcant increase in
Elk-1 activation, as expected. However, in aortae from PEA-
15/ mice, Elk-1 was already signiﬁcantly activated in
unstimulated tissue and did not increase further following
PDGF stimulation. This indicates that Elk-1 activation in
VSMCs from PEA-15/ mice is constitutively increased
under resting conditions, presumably as a result of the
increased ERK1/2 in the nucleus. The increased ERK1/2
nuclear localization and increased Elk-1 activation did not
result in any changes in arterial structure or wall thickness
(data not shown) but could produce altered pathological
responses during stress conditions such as vascular injury.
The Effects of Vascular Injury in PEA-15/ Mice
PEA-15/ and WT mice were subjected to wire injury of the
left carotid artery for 3, 7, or 14 days. Injured carotid arteries
were initially examined using routine microscopy. In the WT
mice, the intima:media ratio from injured carotid arteries was
signiﬁcantly different only at 14 days after injury compared
with arteries from sham-operated WT mice or the contralat-
eral uninjured artery but was unchanged at the earlier time
points (Figure 2A and 2B). In PEA-15/ mice, the intima:-
media ratio was also not different in injured arteries compared
with sham/uninjured arteries at 3 days following vascular
injury. At both 7 and 14 days after injury, however, there was
a signiﬁcant increase in the intima:media ratio in injured
arteries of PEA-15/ mice compared with either the
uninjured contralateral artery or arteries from sham-operated
mice (Figure 2A and 2B). Importantly, when PEA-15/ and
WT mice were directly compared, the rate of neointimal
formation was signiﬁcantly faster, 3 times quicker, in PEA-
15/ mice compared with WT mice (Figure 2C). The medial
layer thickness and the external elastic lamina were
unchanged in PEA-15/ mice compared with WT mice at
all time points examined, indicating that this was predom-
inately caused by increased cellular content (data not shown).
Expression of Phenotypic Marker Proteins
Following Vascular Injury in PEA-15/ Mice
We next examined the expression of proteins relevant to
VSMC phenotype: the proliferative marker PCNA (proliferating
cell nuclear antigen) and smoothelin, a marker of differenti-
ated smooth muscle cells. The expression of these proteins
was examined in carotid arteries from mice following vascular
injury at 3, 7, and 14 days, as described, and assessed by
immunoblotting of arterial homogenates. PCNA expression
was signiﬁcantly increased and, conversely, smoothelin
expression was signiﬁcantly decreased in injured arteries
from PEA-15/ mice at 3 days after vascular injury
compared with sham-operated and uninjured arteries (Fig-
ure 3A). An increase in proliferative markers and a parallel
decrease in differentiation markers switch VSMC phenotype
towards proliferation, as has been established previously.4 In
WT mice, however, both PCNA and smoothelin expression was
similar in injured arteries compared with sham-operated and
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Figure 1. The vasculature from mice deﬁcient in PEA-15 (phosphoprotein enriched in astrocytes 15; PEA-
15/) has altered ERK1/2 (extracellular signal–regulated kinases 1 and 2) signaling pathways. A, ERK1/2
localization and labeled nuclei in unstimulated aortic smooth muscle cells cultured from PEA-15/ and
wild-type (WT) mice. Scale bar=5 lm. Representative image from 3 separate cultures. B, Sections of carotid
artery from either PEA-15/ or WT mice, triple-labeled for ERK1/2, nuclei, and smooth muscle a-actin.
Representative images shown, scale bar=25 lm. Graph displays mean data for nuclear:cytoplasmic ratio
calculated using image analyses comparing arteries from 3 mice. **P<0.01 using Student t test.
C, Activation of ERK1/2 in aortae from PEA-15/ and WT mice stimulated with 50 ng/mL PDGF (platelet-
derived growth factor) for 15 minutes at 37°C ex vivo. Representative immunoblots for phosphorylated
ERK1/2, total ERK1/2, and GAPDH are shown. Mean data of ERK1/2 activation are expressed as a ratio of
GAPDH, n=4. *P<0.05 and **P<0.01 using 1-way ANOVA and Newman–Keuls post hoc test. D,
Electromobility shift assay of aortic nuclear extracts from PEA-15/ and WT aortae to determine Elk-1
(ETS-like gene-1) activation. Aortae were stimulated with 50 ng/mL PDGF for 15 minutes at 37°C ex vivo.
The arrowhead on the representative image denotes a gel shift indicating Elk-1 activation. Mean data are
expressed as a fold increase over density of cold probe band (n=3). *P<0.05 using 1-way ANOVA and
Newman–Keuls post hoc test.
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uninjured arteries at 3 days after vascular injury. This early
phenotypic switch at day 3 after injury in the knockout
animals presumably results in the increased rate of develop-
ment in the media:intima ratio (compared with WT) observed
at day 7 after injury (Figure 2C). At day 7 after injury, PCNA
expression was signiﬁcantly increased in injured arteries
compared with sham-operated or uninjured arteries in both
knockout and WT mice; however, increased PCNA expression
remained signiﬁcantly greater in PEA-15/ mice (Figure 3B).
Smoothelin expression was also signiﬁcantly decreased to the
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Figure 2. Mice deﬁcient in PEA-15 (phosphoprotein enriched in astrocytes 15; PEA-15/) have an
increased rate of development of neointimal hyperplasia. A, Representative hematoxylin and eosin–stained
sections of mouse carotid arteries from either PEA-15/ and wild-type (WT) mice at 3, 7, and 14 days after
wire-induced vascular injury. Scale bar=100 lm. B, Mean data on the intima:media ratio in injured carotid
arteries fromPEA-15/orwild-typemice at 3, 7, and14 days following vascular injury (statistical signiﬁcance
is shownonly for injuredvsshamvessels), n=6.*P<0.05and**P<0.01using2-wayANOVAandBonferroni post
hoc test. C, Mean data directly comparing the rate of intima development in injured carotid arteries from PEA-
15/ and WT mice, n=6. *P<0.05 using 1-way ANOVA and Newman–Keuls post hoc test.
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Figure 3. Arteries frommice deﬁcient in PEA-15 (phosphoprotein enriched in astrocytes 15; PEA-15/) undergoing neointimal hyperplasia have
increased proliferation markers and decreased smooth muscle differentiation markers. The expression of the proliferation marker PCNA
(proliferating cell nuclear antigen) and the smooth muscle differentiation marker smoothelin were determined in carotid arteries from PEA-15/
andwild-type (WT) mice following vascular injury and compared with the contralateral uninjured artery or arteries from sham-operatedmice. Protein
expression was assessed at 3 time points after injury: (A) 3 days, (B) 7 days, and (C) 14 days. Representative immunoblots are shown for each time
point, and mean data are expressed as a ratio of GAPDH protein expression, n=3 for each treatment. Statistical comparisons are shown only for
sham vs injured arteries. *P<0.05 and **P<0.01 using 2-way ANOVA and Bonferroni post hoc test for all graphs.
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same extent in injured arteries from PEA-15/ and WT mice
after 7 days of vascular injury. Following 14 days of vascular
injury, PCNA expression was unchanged in injured arteries
from WT mice compared with sham-operated or uninjured
arteries; however, in injured arteries from PEA-15/ mice,
PCNA expression was still signiﬁcantly increased compared
with sham-operated and uninjured arteries (Figure 3C).
Smoothelin expression in injured arteries at 14 days after
vascular injury was similarly decreased in both PEA-15/
and WT mice. These results indicate that, following vascular
injury, VSMCs from PEA-15/ mice switch more rapidly to a
proliferative, less differentiated phenotype, and this is
sustained throughout neointimal development.
Cellular Architecture of Neointimal Hyperplasia in
PEA-15/ Mice
The cellular architecture of injured arteries from PEA-15/
mice was assessed further by examining the collagen content.
Decreased collagen content would allow faster development of
neointimal hyperplasia, as migrating cells can move more
quickly into neointima. In uninjured arteries, there was no
difference in collagen content from WT mice compared with
PEA-15/ mice, as assessed using Masson’s trichrome–
stained ﬁxed sections (Figure 4A). The collagen content of
injured arteries fromWTmice did not change over the course of
neointimal hyperplasia development; however, in PEA-15/
mice at day 3 after injury, the collagen content was signiﬁcantly
less compared with WT arteries (Figure 4A). At day 7 following
arterial injury, collagen content in PEA-15/ mice carotid
arteries was signiﬁcantly increased compared with day 3 and
was similar to the collagen content in injured arteries from WT
mice at day 7 after injury. This was also the case at 14 days
after vascular injury. Collagen in sham-operated arteries was
similar to levels in PEA-15/ and WT mice and unchanged at
all time points examined (data not shown).
An increase in the number of smooth muscle cells would
indicate that neointimal hyperplasia is, at least in part, caused
by VSMC proliferation. The number of smooth muscle cells
per arterial cross-section was determined using sections
labeled with anti–smooth muscle a-actin antibody. Only cells
in the neointimal layer were counted. At day 3 following
vascular injury, very few smooth muscle a-actin–positive cells
were in the neointima of either PEA-15/ or WT mice
(Figure 4B). At day 7 after injury, the number of smooth
muscle a-actin–positive cells was signiﬁcantly increased 3-
fold in the neointima of arteries from PEA-15/ mice
compared with WT mice. By day 14 after injury, the number of
smooth muscle a-actin–positive cells in the neointima was
similar in PEA-15/ and WT mice. Importantly, in PEA-15/
mice, there was no signiﬁcant difference between the number
of smooth muscle cells at day 7 compared with day 14; this
was maximal at day 7, correlating with the changes in
intima:media ratio (as demonstrated in Figure 2). This ﬁnding
contrasts with a signiﬁcantly increasing number of smooth
muscle cells until day 14 in neointima of WT mice.
Regulation of PEA-15 Expression During the
Development of Neointimal Hyperplasia in Mice
Although PEA-15/ mice have an increased rate of neoin-
timal development following vascular injury, this would be of
pathological relevance only if PEA-15 expression were
regulated during this process in WT tissues. We previously
demonstrated that PEA-15 expression is a critical regulator of
VSMC proliferation and differentiation in vitro.9 A decrease in
PEA-15 expression in primary cultured VSMCs increases
proliferation.9 In the current study, we assessed whether the
expression of PEA-15 is altered during the development of
neointimal hyperplasia, a process that is dependent on VSMC
proliferation.5 WT mice were subjected to wire injury of the
left carotid artery for 3, 7, or 14 days, as described previously
by our laboratory.18 The expression of PEA-15 was examined
in injured versus sham-operated carotid arteries. At 3 days
after injury, PEA-15 expression in carotid arteries was
signiﬁcantly decreased by 3-fold compared with sham-
operated or uninjured arteries, as measured by immunoblot-
ting (Figure 5A). At days 7 and 14 following vascular injury,
PEA-15 expression was not signiﬁcantly different from that in
sham-operated arteries. This indicates that PEA-15 expres-
sion is decreased at an early time point in neointimal
development, before any increase in the intima:media ratio
occurs in WT mice (Figure 2B). This early decrease in PEA-15
expression during neointimal development occurs, at least in
part, in VSMCs as assessed by immunolabeling of injured
arterial sections with anti–PEA-15 antibody (Figure 5B).
Double-labeling experiments with anti–smooth muscle a-actin
antibody conﬁrmed these cells in the medial layers as almost
exclusively smooth muscle cells (results not shown). This
decrease in PEA-15 expression would be expected to initiate
a phenotypic switch in VSMCs toward proliferation, as
observed previously in cultured VSMCs.9 Based on our data
from PEA-15/ mice (Figure 1), this decreased expression
of PEA-15 should result in increased ERK1/2 localization to
the nucleus (Figure 1). We assessed ERK1/2 immunolocal-
ization in arterial sections (Figure 5C). In sections from sham-
operated mice at 3 days, ERK1/2 localization was predom-
inantly cytoplasmic, whereas this switched to predominantly
nuclear localization in injured arteries at 3 days (Figure 5C).
This was reﬂected in a signiﬁcantly increased nuclear:cyto-
plasmic ratio in injured arteries compared with sham-
operated mice. Such ERK1/2 nuclear localization would
increase ERK1/2-mediated gene transcription, leading to
VSMC proliferation (Figure 1).9
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Regulation of PEA-15 Expression in Neointimal
Hyperplasia in Human Blood Vessels Ex Vivo
To determine whether PEA-15 expression is regulated in
neointimal hyperplasia in human blood vessels, we used
human saphenous vein incubated ex vivo under conditions
that induce hyperplasia, as described previously (Fig-
ure 6A).19 After 14 days in culture, human saphenous vein
sections had decreased expression of PEA-15, as assessed by
immunoblotting (Figure 6B). In addition, a marker of
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Figure 4. Collagen content is decreased and smoothmuscle cell number is increased in arteries frommice
deﬁcient in PEA-15 (phosphoprotein enriched in astrocytes 15; PEA-15/) undergoing neointimal
hyperplasia. A, The collagen content was determined in PEA-15/ and wild-type (WT) mice by analyzing
sections of arteries stained with Masson’s trichrome (representative images are shown). Arteries are
compared frommice at 3, 7, and 14 days after injury. Collagen is shown as a percentage of area of the total
arterial wall, n=6 for each treatment. *P<0.05 and **P<0.01 using 1-way ANOVA and Newman–Keuls post
hoc test. B, Smooth muscle cell content was assessed by counting the number of cells stained positive for
anti–smoothmusclea-actin antibody in the neointimaonly (notmedia) at each timepoint. Thiswas compared
in PEA-15/ andWTmice at 3, 7, and 14 days after injury, n=4 for each treatment. For clarity, only relevant
signiﬁcant comparisons are shown. *P<0.05 using 1-way ANOVA and Newman–Keuls post hoc test.
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Figure 5. PEA-15 (phosphoprotein enriched in astrocytes 15) expression is dynamically regulated in
mouse arteries during the development of neointimal hyperplasia. A, PEA-15 expression in injured
arteries from wild-type (WT) mice at 3, 7, and 14 days after injury was compared with expression in
arteries from sham-operated mice and uninjured arteries. Representative immunoblots are shown, and
mean data are expressed as a ratio of GAPDH expression (n=6). **P<0.01using 1-way ANOVA and
Newman–Keuls post hoc test. B, PEA-15 localization and expression was examined in sections from
carotid arteries at 3 days following vascular injury in WT mice and compared with arteries from sham-
operated WT mice. Representative confocal images are shown, scale bar=100 mm. Mean data for PEA-
15 expression from confocal images are expressed as fold change in relative ﬂuorescence, n=5.
*P<0.05 using Student t test. C, ERK1/2 (extracellular signal–regulated kinases 1 and 2) localization in
sections of injured arteries from WT mice was compared with sections of arteries from sham animals
using confocal immunoﬂuorescence. Representative parallel confocal images are shown for ERK1/2 and
DAPI (40,6-diamidino-2-phenylindole; nuclei), scale bar=25 lm. Mean ERK1/2 localization is presented
as the intensity ratio of nuclear/cytoplasmic localization, n=6. *P<0.05 using Student t test.
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proliferation, Ki67, was signiﬁcantly increased. We next
examined whether the decreased expression of PEA-15 was
a result of PEA-15 gene repression. Using real-time
polymerase chain reaction, PEA-15 gene expression was also
signiﬁcantly decreased (Figure 6C). This was complemented
by an increase in Ki67 gene expression.
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Figure 6. PEA-15 (phosphoprotein enriched in astrocytes 15) expression is dynamically regulated in
human arteries in an ex vivo model of neointimal hyperplasia. A, Representative image of human saphenous
vein segments from the same patient, comparing the wall thickness of control and 14-day organ-cultured
segments. Scale bar=400 lm. B, Immunoblots from control and organ-cultured vein segments to determine
expression of PEA-15, Ki67 (proliferative marker), and GAPDH. Representative immunoblots are shown.
Mean data for PEA-15 and Ki67 protein expression are calculated as a ratio of GAPDH, n=6. *P<0.05 and
**P<0.01 using Student t test. C, Gene expression of PEA-15 and Ki67 in control and organ-cultured human
saphenous vein segments determined by quantatitive polymerase chain reaction. Results are expressed as
a ratio of GAPDH, n=6. *P<0.05 and **P<0.01 using Student t test.
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Discussion
The intracellular phosphoprotein PEA-15 acts as a cytoplas-
mic tether for ERK1/2, thereby regulating nuclear localization
and, subsequently, nuclear-dependent ERK1/2 signaling.10–12
We previously demonstrated in VSMCs that this tethering role
can potentially regulate phenotypic changes in vitro, leading
to an increase in ERK1/2-dependent transcription and
increased proliferation.9 In the current study, we demon-
strated that PEA-15 is an important regulator of the response
to vascular injury. Mice lacking PEA-15 develop neointimal
hyperplasia at a 3-fold increased rate due to, at least in part,
increased proliferation of VSMCs. In addition, in WT mice,
vascular injury results in decreased PEA-15 expression that
occurs before signiﬁcant development of neointimal hyper-
plasia, indicating a potential role in the initiation of this
process. This decreased expression of PEA-15 was reﬂected
in an ex vivo model of neointimal hyperplasia in human
saphenous veins. This indicates that PEA-15 expression is a
vasoprotective mediator in arteries and could limit neointimal
hyperplasia at an early stage. In addition, PEA-15 expression
is attenuated following vascular injury, and this decreased
expression can drive increased proliferation of VSMCs. This
would directly contribute to neointimal hyperplasia and,
ultimately, restenosis.
Although PEA-15/ mice have no obvious cardiovascular
phenotype, isolated arteries reveal changes in intracellular
signaling that would be expected to potentially regulate
vascular structure and function. ERK1/2 localization is
signiﬁcantly shifted toward the nucleus in VSMCs, observed
in both primary culture and in freshly isolated arteries. This
mirrors our previous ﬁndings in cultured human VSMCs, in
which PEA-15 expression was decreased by small interfering
RNA, and is similar to those in T-lymphocytes from PEA-15/
mice.9,20,21 These changes in arteries from PEA-15/ mice
resulted in changes to ERK1/2 activation and signaling by the
mitogen PDGF. In VSMCs, although reduced ERK1/2 activa-
tion was reﬂected in a lack of increase in PDGF-induced Elk-1
activation, the resting level of Elk-1 activation was signiﬁ-
cantly increased in unstimulated arteries from PEA-15/
mice compared with WT mice. A possible explanation for this
apparent dichotomy could be the resting level of phosphory-
lated (activated) ERK1/2 present in VSMCs. This resting level
of activated ERK1/2, coupled with an increased nuclear
translocation of total ERK1/2 (some of which will be
phosphorylated), could be sufﬁcient to result in this observed
increase in basal Elk-1 activation. Previous studies have
shown that elevated basal Elk-1 would lead to a more
proliferative VSMC phenotype.7 We found no changes in
artery structure in uninjured vessels from PEA-15/ mice,
which presumably reﬂect adaptation of further downstream
mediators allowing normal arterial development. Elevated
basal Elk-1 activation, however, could predispose PEA-15/
mice to an exaggerated response by vascular stress, namely,
the VSMCs persist in a “primed” state. In summary, although
no obvious differences were detected in arteries from PEA-
15/ mice, intracellular changes suggest that, under appro-
priate circumstances, such differences could arise.
In agreement with our proposed role for PEA-15 in VSMCs,
when PEA-15/ mice were subjected to vascular injury, an
increased rate (3-fold) of neointimal hyperplasia was
observed. This was maximal at 7 days after injury, compared
to a maximal injury response of at least 14 days for WT
mice.18 The increase in neointimal area was paralleled by an
increase in number of smooth muscle cells, indicating that the
neointima is predominantly due to an increase in VSMCs.
Indeed the majority of cells in the neointima were positive for
a smooth muscle marker. Collagen content was decreased in
PEA-15/ mice at this early stage and the consequences of
this are not clear. This could affect VSMC migration with lower
collagen content presumably enabling faster migration of
VSMCs in to the growing neointima.22 It is however clear that
decreased PEA-15 expression increases VSMC proliferation
in vivo, conﬁrming our previous in vitro study.9
Our ﬁndings that the accelerated vascular response to
injury in PEA-15/ mice was produced predominantly by
proliferation of VSMCs was further supported by a parallel
increase in the expression of a proliferative marker and,
conversely, a decrease of a VSMC differentiation marker at
3 days after injury. These early changes occurred before any
increase in intimal growth was observed. Both changes are
known to be directly associated with the initiation of VSMC
proliferation.4 This suggests that the increased ERK1/
2-dependent transcription (due to its prolonged nuclear
localization) in the vasculature of the PEA-15/ mice is
driving VSMC phenotypic change toward a proliferative state
at a faster rate. A recent study demonstrated that PEA-15
downregulation progresses cells through the cell cycle from
G1 to S-phase via increased ERK1/2 nuclear translocation.23
ERK1/2 activation is known to be critical in maintaining
neointimal formation, as localized ERK1/2 inhibition sup-
presses the response to vascular injury.24 In addition, the
reversal of the VSMC proliferative response (as assessed by
proliferative marker expression) in WT mice occurs as
neointimal development reaches its maximum; however, in
the arteries of PEA-15/ mice, proliferation is maintained
throughout the time course (although VSMC proliferation is
physically limited because of complete occupation of the
lumen). This indicates that PEA-15 expression could also play
an important role in switching off the response to vascular
injury. These overall effects of PEA-15 expression on vascular
injury responses generally agree with studies on PEA-15 in
other cell types. In Jurkat T cells lacking PEA-15 expression,
stimulation with interleukin 2 produced an enhanced
DOI: 10.1161/JAHA.117.006936 Journal of the American Heart Association 12
PEA-15 Is a Protective Mediator in the Vasculature Greig et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on Septem
ber 12, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
proliferative response.20 In cancer, the role of PEA-15 is
complex and is partially related to phosphorylation status;
however, it has been reported that decreased PEA-15
expression in some cancer cells is related to increased
proliferation and invasiveness.25,26 Together, the studies cited
and our own data indicate that PEA-15 may be more generally
involved in acting as a brake on cell proliferation in responses
to several different cellular stresses.
In addition to uncovering the protective role of PEA-15 in
the vasculature, we further revealed that PEA-15 expression
is dynamically regulated during the development of neoin-
timal hyperplasia. Following vascular injury in WT mice,
PEA-15 expression was signiﬁcantly decreased in VSMCs of
carotid arteries at day 3 after injury compared with sham-
operated animals but recovered to levels in sham-operated
animals by day 7. At this early time point, ERK1/2 also had
signiﬁcantly increased nuclear localization that could result
in increased VSMC proliferation, as have previously demon-
strated in cultured cells.9 Because this decrease in PEA-15
expression occurs before any changes in arterial structure
are observed in the injured arteries, a primary role in the
vascular injury response is indicated. The delay until day 7
after injury before increased proliferation is physically
apparent in the intima:media ratio most likely reﬂects the
time taken from the initiation of the response (including the
decreased PEA-15 response) to sufﬁcient migration and
proliferation to follow. The mechanisms involved in the
decrease in PEA-15 expression, possibly via gene repres-
sion, are not known. Very few studies have examined the
regulation of PEA-15 expression at the transcriptional level,
although hepatocyte nuclear factor 4a has been suggested
as a repressive factor.27 Further studies are required in
VSMCs to fully elucidate PEA-15 transcriptional regulation.
The translational potential of our ﬁndings in mice were
extended further using an ex vivo model of hyperplasia in
human saphenous veins segments. These results demon-
strate that PEA-15 expression is also similarly decreased in
human VSMCs under high-serum conditions, and this may
occur, at least in part, via PEA-15 gene repression.
Although this ex vivo model has limitations compared with
vascular injury in vivo, it points toward a role in human
vascular injury.
Although VSMCs are involved in the accelerated response
to vascular injury, other cell types may also have a role
including endothelial cells. PEA-15 is expressed in endothelial
cells, and expression may be regulated during phenotypic
change, although this is still not clear.28 We have not
investigated the rate of recovery of the endothelial cell layer
following vascular injury; however, increased endothelial cell
proliferation (similar to the increased proliferation in VSMCs),
may be a beneﬁt and would be expected induce more efﬁcient
repair of the endothelial barrier.2 Nevertheless, in the current
experiments, the overall effect on neointimal hyperplasia in
PEA-15/ mice was detrimental, suggesting that any
beneﬁcial effects in other cell types were not sufﬁcient to
overcome the increased proliferation of VSMCs. The role of
PEA-15 in other cell types within the vasculature is not clear
and requires further investigation.
Taken together our results indicate, for the ﬁrst time, that
PEA-15 is a protective mediator in the vasculature and acts, at
least in part, by inhibiting ERK1/2-dependent nuclear signal-
ing in VSMCs. This may also occur partly via an inhibitory role
in inﬂammation. In addition, PEA-15 expression is dynamically
repressed in the early stages of neointima hyperplasia,
indicating a primary role in this injury process. This evidence
indicates that PEA-15 is a novel therapeutic target to prevent
restenosis. Maintaining PEA-15 expression immediately fol-
lowing angioplasty and stent placement could protect the
vasculature at the critical initiation stage of neointimal
hyperplasia when the physiologically protective role of PEA-
15 is lost.
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